PowerBeat M Series is a compact, lightweight, reliable, and robust portable semi-automatic external defibrillator (including the M1 Professional version and the M3 General version). Designed to be the size of a smartphone and weighing just 0.7kg, it achieves the same therapeutic effects as traditional-sized AEDs and ensures convenient portability and efficient mobility, providing effective emergency assistance to sudden cardiac arrest patients anytime, anywhere. It features intelligent voice guidance and one-touch defibrillation functions, making it user-friendly even for non-professionals.

ViVest is a pioneering medical technology company at the forefront of advancing the prevention and treatment of ventricular arrhythmia, as well as providing cutting-edge cardiac rhythm data services. Our unwavering commitment lies in delivering comprehensive and groundbreaking solutions for the global prevention, monitoring, treatment, and rehabilitation of ventricular arrhythmia. Leveraging the groundbreaking innovation of wearable cardioverter defibrillators and recognizing the pressing clinical imperatives, ViVest has achieved a historic milestone as the first company in China to independently develop wearable cardioverter defibrillators (WCDs). Looking ahead, our vision extends to the creation of the world's premier multi-parameter sudden cardiac death risk assessment system, propelled by the promotion of wearable ventricular arrhythmia products and remote data service management. This forward-looking approach positions ViVest at the vanguard of transforming the treatment of sudden cardiac death, shifting from passive response to precise treatment of ventricular arrhythmia rhythm management, seamlessly integrating prevention and treatment.

ViVest is a pioneering medical technology company at the forefront of advancing the prevention and treatment of ventricular arrhythmia, as well as providing cutting-edge cardiac rhythm data services. Our unwavering commitment lies in delivering comprehensive and groundbreaking solutions for the global prevention, monitoring, treatment, and rehabilitation of ventricular arrhythmia. Leveraging the groundbreaking innovation of wearable cardioverter defibrillators and recognizing the pressing clinical imperatives, ViVest has achieved a historic milestone as the first company in China to independently develop wearable cardioverter defibrillators (WCDs). Looking ahead, our vision extends to the creation of the world's premier multi-parameter sudden cardiac death risk assessment system, propelled by the promotion of wearable ventricular arrhythmia products and remote data service management. This forward-looking approach positions ViVest at the vanguard of transforming the treatment of sudden cardiac death, shifting from passive response to precise treatment of ventricular arrhythmia rhythm management, seamlessly integrating prevention and treatment.